Evaluation of Immunologic Response following COVID-19 Vaccination in Children, Adolescents, and Young Adults with Cancer

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the bodys immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the bodys natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or boosts (extra vaccine shots) may strengthen or diminish the bodys protective immune response. This study may help researchers learn more about how the bodys immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.

Disease Sites:

Pediatrics

Staging:

N/A

Age Group:

Both

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Esbenshade, Adam

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

02-17-2023

Trial Type:

Other

Protocol ID:

COGACCL21C2

National Clinical Trial ID:

NCT05228275

Eligibility

Ages Eligible for Study:

6 Months

Genders Eligible for Study:

BOTH

Accepts Healthy Volunteers?:

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Evaluation of Immunologic Response following COVID-19 Vaccination in Children, Adolescents, and Young Adults with Cancer

Eligibility